MicroRNA-224 orchestrates BMP and TGFβ signaling and is a therapeutic target in preclinical pulmonary arterial hypertension.

MicroRNA-224-5p promotes pulmonary vascular remodeling and worsens PAH, with inhibition reducing disease severity in preclinical models.

• Why it matters: PAH is a deadly disease with limited targeted treatments, and understanding molecular regulators like microRNAs could lead to new therapies.
• What they did: The study measured miR-224 levels in PAH patients and models, manipulated its expression using viral vectors and antisense oligonucleotides, and examined its effects on signaling pathways and vascular remodeling.
• The result: Inhibiting miR-224 improved vascular structure and heart function, revealing it as a promising therapeutic target to restore BMP/TGFβ signaling balance in PAH.